Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors

[1]  C. Zahnow,et al.  Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma , 2018, Oncotarget.

[2]  Liang Xu,et al.  GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells , 2017, Experimental cell research.

[3]  S. Fallahpour,et al.  Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. , 2017, CMAJ open.

[4]  S. Gurunathan,et al.  Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer , 2017, International journal of nanomedicine.

[5]  R. Rad,et al.  HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer , 2017, Oncogene.

[6]  Jun Du,et al.  Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells. , 2016, Cellular signalling.

[7]  A. Marcus,et al.  Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers , 2016, Oncotarget.

[8]  J. Koo,et al.  Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology , 2016, Journal of Translational Medicine.

[9]  Fan Zhang,et al.  Loss of TINCR expression promotes proliferation, metastasis through activating EpCAM cleavage in colorectal cancer , 2016, Oncotarget.

[10]  Lianhong Li,et al.  MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  J. Russo,et al.  Development and characterization of two human triple‐negative breast cancer cell lines with highly tumorigenic and metastatic capabilities , 2016, Cancer medicine.

[12]  X. Wan,et al.  Mutant p53 induces EZH2 expression and promotes epithelial–mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing , 2015, Oncotarget.

[13]  N. Neamati,et al.  Guadecitabine (SGI‐110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin , 2015, Molecular oncology.

[14]  Yul Ri Chung,et al.  Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. , 2015, Human pathology.

[15]  Stephen Yu,et al.  Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells , 2015, Molecular Cancer Therapeutics.

[16]  Raja Jothi,et al.  DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis , 2015, Nature Communications.

[17]  B. Paluch,et al.  Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts , 2015, Epigenetics.

[18]  Justin N. Treas,et al.  Potentiation of growth inhibition and epigenetic modulation by combination of green tea polyphenol and 5-aza-2′-deoxycytidine in human breast cancer cells , 2015, Breast Cancer Research and Treatment.

[19]  O. Olopade,et al.  β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells , 2015, PloS one.

[20]  D. Matei,et al.  TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells , 2014, Epigenetics.

[21]  S. Belinsky,et al.  SGI‐110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome , 2014, International journal of cancer.

[22]  J. Karbach,et al.  Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. , 2014, Leukemia research.

[23]  D. Matei,et al.  The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer , 2014, Clinical Cancer Research.

[24]  D. Medici,et al.  Signaling mechanisms of the epithelial-mesenchymal transition , 2014, Science Signaling.

[25]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[26]  V. Thakur,et al.  Multifaceted role of EZH2 in breast and prostate tumorigenesis , 2013, Epigenetics.

[27]  M. Espié,et al.  Distinct tumor protein p53 mutants in breast cancer subgroups , 2013, International journal of cancer.

[28]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[29]  P. Dong,et al.  Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis , 2012, Oncogene.

[30]  G. Sabnis,et al.  Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin , 2013, Breast Cancer Research and Treatment.

[31]  Cun-Yu Wang,et al.  Histone Demethylase KDM6B Promotes Epithelial-Mesenchymal Transition* , 2012, The Journal of Biological Chemistry.

[32]  M. Ringnér,et al.  Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes , 2012, Molecular oncology.

[33]  F. André,et al.  Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Manjili,et al.  CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. , 2012, Human pathology.

[35]  H. Friess,et al.  Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer , 2011, Gut.

[36]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[37]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[38]  M-T Lau,et al.  Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells , 2011, Oncogene.

[39]  Tae Jin Lee,et al.  p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2 , 2011, The Journal of experimental medicine.

[40]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[41]  Sendurai A Mani,et al.  Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression , 2011, Breast Cancer Research.

[42]  J. Qin,et al.  The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis , 2011, Cell Research.

[43]  M. Hung,et al.  p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.

[44]  R. Kurzrock,et al.  MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo , 2010, Molecular Cancer Therapeutics.

[45]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[46]  Hans Clevers,et al.  Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines , 2010, Breast Cancer Research and Treatment.

[47]  N Harbeck,et al.  Triple-negative breast cancer--current status and future directions. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Bolin Liu,et al.  Experimental Therapeutics, Molecular Targets, and Chemical Biology Hdac Inhibitor Sndx-275 Induces Apoptosis in Erbb2-overexpressing Breast Cancer Cells via Down-regulation of Erbb3 Expression , 2022 .

[49]  Markus Munz,et al.  The emerging role of EpCAM in cancer and stem cell signaling. , 2009, Cancer research.

[50]  Brigitte Mack,et al.  Nuclear signalling by tumour-associated antigen EpCAM , 2009, Nature Cell Biology.

[51]  H. Horlings,et al.  EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer , 2008, Breast Cancer Research.

[52]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[53]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[54]  P. V. van Diest,et al.  Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. , 2008, Biochemical and biophysical research communications.

[55]  Jiong Wu,et al.  ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor , 2008, Journal of Cancer Research and Clinical Oncology.

[56]  Thomas R. Sutter,et al.  Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol. , 2007, Cancer research.

[57]  J. Russo,et al.  Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol. , 2007, Cancer research.

[58]  P. Eilers,et al.  E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines , 2006, British Journal of Cancer.

[59]  E. Ballestar,et al.  Snail Mediates E-Cadherin Repression by the Recruitment of the Sin3A/Histone Deacetylase 1 (HDAC1)/HDAC2 Complex , 2004, Molecular and Cellular Biology.

[60]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Yang Shi,et al.  Coordinated histone modifications mediated by a CtBP co-repressor complex , 2003, Nature.

[62]  E. Fearon,et al.  The SLUG zinc-finger protein represses E-cadherin in breast cancer. , 2002, Cancer research.

[63]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Y. Ip,et al.  Human Slug Is a Repressor That Localizes to Sites of Active Transcription , 2000, Molecular and Cellular Biology.